SCHEMBL13615574

SCHEMBL13615574

NCCc1noc(-c2ccccc2)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.66
RAB9A P51151 5/20 0.66
SMN1; SMN2 Q16637 5/20 0.66
MAPT P10636 2/20 0.66
PKM P14618 2/20 0.66
HSD17B10 Q99714 2/20 0.66
ALDH1A1 P00352 2/20 0.66
KDM4E B2RXH2 1/20 0.66
HPGD P15428 1/20 0.66
NOTUM Q6P988 2/20 0.64
NR1H4 Q96RI1 2/20 0.53
HTT P42858 1/20 0.50
HTR1A P08908 1/20 0.47
HTR2C P28335 1/20 0.47
LMNA P02545 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
FFAR1 O14842 1/20 0.46
NFKB1 P19838 2/20 0.45
NFKB2 Q00653 2/20 0.45
RELA Q04206 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL14736295 0.98 NPC1 (0.64) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL21776935 0.87 NOTUM (0.70) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL990519 0.84 NPC1 (0.68) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL9005927 0.82 NOTUM (0.74) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL10115511 0.82 NPC1 (0.93) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL15058774 0.78 FFAR1 (0.66) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL16284866 0.78 NPC1 (0.65) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL13188154 0.78 NPC1 (0.65) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL7254229 0.78 NOTUM (0.68) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL120396 0.78 NOTUM (0.68) NPC1RAB9ASMN1; SMN2MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772510-B2 PDE10 modulators HOFFMANN-LA ROCHE INC. (US) 2014-07-08 US claimed
US-20130059833-A1 PDE10 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 US claimed
EP-2753604-B1 PDE10 MODULATORS HOFFMANN LA ROCHE (CH) 2015-08-19 EP disclosed
US-8772510-B2 PDE10 modulators HOFFMANN-LA ROCHE INC. (US) 2014-07-08 US disclosed
EP-2574607-A1 PDE10 modulators F. Hoffmann-La Roche AG (CH) 2013-04-03 EP disclosed
WO-2013034506-A1 PDE10 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-14 WO disclosed
US-20130059833-A1 PDE10 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 US disclosed
WO-2009133127-A1 FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS MERCK SERONO S.A. (CH) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059833-A1 PDE10 MODULATORS PDE10A, PDE5A, PDE2A NPC1 2474/4885RAB9A 109/4885SMN1; SMN2 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.